What cardiovascular and kidney benefits, harms, and uncertainties are reported for GLP-1 receptor agonists in adults with type 2 diabetes?
A meta-analysis of eight placebo-controlled cardiovascular outcome trials involving 60,080 participants found that GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 14% (HR 0.86, 95% CI 0.80-0.93). It also reported relative reductions in all-cause mortality, heart-failure admission, and a composite kidney outcome. [1]
In LEADER, liraglutide reduced the primary MACE outcome from 14.9% to 13.0% over a median 3.8 years (HR 0.87, 95% CI 0.78-0.97), with lower cardiovascular and all-cause mortality. Gastrointestinal events were the most common reason for discontinuation. [2]
REWIND enrolled a broader risk population: only about one third had a previous cardiovascular event. Dulaglutide reduced MACE from 13.4% to 12.0% over 5.4 years (HR 0.88, 95% CI 0.79-0.99), while all-cause mortality was not significantly different. Gastrointestinal adverse events were more frequent with dulaglutide. [3]
SUSTAIN-6 reported fewer MACE and fewer new or worsening nephropathy events with semaglutide, but more diabetic-retinopathy complications (3.0% versus 1.8%; HR 1.76, 95% CI 1.11-2.78). This agent-specific safety signal should not be hidden inside a class-average benefit estimate. [4]
The 2023 ESC guideline incorporates evidence from large cardiovascular outcome trials into risk-focused management of cardiovascular and cardiorenal disease in people with diabetes. Guideline context helps translate trial evidence, but it does not make every GLP-1 receptor agonist or every patient population interchangeable. [5]
- Most cardiovascular outcome trials enrolled people with established cardiovascular disease or elevated risk; absolute benefit is likely smaller in lower-risk populations.
- Pooled relative effects do not replace agent-specific evidence, baseline-risk assessment, or absolute event rates.
- Gastrointestinal intolerance is common, and the retinopathy signal in SUSTAIN-6 requires clinical context rather than simple class-wide extrapolation.
- The landmark trials were largely industry funded and generally compared treatment with placebo on top of standard care.